Ab Initio Modeling: Predicting Target Molecule Structures for Drug Discovery, Slides of Biology

Ab Initio Modeling is a computational approach used by Creative Biostructure to predict the three-dimensional structures of target proteins and complexes, providing valuable insights into their structure-function relationships for drug discovery. This technique is particularly useful when experimental methods for determining structures encounter technical difficulties.

Typology: Slides

2019/2020

Uploaded on 12/02/2020

Joannaz
Joannaz 🇺🇸

4.5

(2)

179 documents

1 / 6

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
Ab Initio Modeling
pf3
pf4
pf5

Partial preview of the text

Download Ab Initio Modeling: Predicting Target Molecule Structures for Drug Discovery and more Slides Biology in PDF only on Docsity!

Ab Initio Modeling

Structural Modeling of Target Molecule Obtaining structural information about individual target proteins or complexes of target proteins with other molecules ( e.g. , proteins, nucleic acids, and small molecules) can provide insight into the structure-function relationship of the target protein and the underlying mechanism of interaction, which is significant for drug discovery and development. However, it is relatively difficult and time- consuming to determine the three-dimensional (3D) structure of biological macromolecules through experimental approaches such as X-ray crystallography, cryo-electron microscopy, or NMR spectroscopy. As a structure- based drug discovery CRO, Creative Biostructure not only provides experimental techniques to determine the structure, but also utilizes high- performance computing tools to predict the structural model of the target molecule, collect information about dynamic properties, and predict binding patterns and affinity between target proteins and other interacting molecules.

Creative Biostructure has extensive expertise and rich experience in generating structural models of various types of proteins and complexes. We mainly adopt two strategies for building target models, namely homology modeling and ab initio modeling, and we can also customize and perform target modeling according to customer requirements. We ensure the reliability of the resulting model for downstream applications, such as virtual screening and structure-based drug design guidance, through rigorous parameter setting and iterative computational validation and simulation.